Product Details:
Payment & Shipping Terms:
|
CAS: | 164656-23-9 | Assay: | 99% |
---|---|---|---|
Molecular Formula: | C27H30F6N2O2 | Molecular Weight: | 528.53 |
Appearance: | White Or Almost White Crystalline Powder | ||
High Light: | anti estrogen drugs bodybuilding,anti estrogen bodybuilding |
Health Care Male Sex Hormones Raw Material Avodart Dutasteride CAS 164656-23-9
Description:
Dutasteride (trademark name Avodart) is a dual 5-α reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT).Used for benign prostatic hyperplasia;however,it increases the risk of erectile dysfunction and decreased sexual desire.
Dutasteride useful for the symptoms of benign prostatic hyperplasia (BPH);colloquially known as an "enlarged prostate".In those who are being regularly screened 5-alpha-reductase inhibitor (finasteride and dutasteride) reduce the overall risk of being diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases.
Applications:
Dutasteride,along with Finasteride is a 5-alpha-Reductase inhibitor which are a group of drugs with anti-androgenic properties which inhibit the conversion of testosterone into dihydrotestosterone (DHT).This is the same chemical found in Proscar and Propecia and is used in the treatment hyperplasia and androgenic alopecia.Because these drugs reduce levels of dihydrotestosterone (DHT) they are used to prevent and treat hairloss.It is most commonly used to treat enlarged prostate glands.
While the potential for positive,negative or neutral changes to the potential risk of developing prostate cancer with dutasteride has not been established,evidence has suggested it may temporarily reduce the growth and prevalence of benign prostate tumors,but could also mask the early detection of prostate cancer.
The primary area for concern is for patients who may develop prostate cancer whilst taking dutasteride for benign prostatic hyperplasia,which in turn could delay diagnosis and early treatment of the prostate cancer,thereby potentially increasing the risk of these patients developing high-grade prostate cancer.
COA
Test Items | Specification | Test Results |
Description | White or almost white powder | Complies |
Identification | Meet the requirements | Complies |
Loss on drying | ≤0.5% | 0.2% |
Melting range | 246ºC~252ºC | 246ºC~248ºC |
Heavy metals | ≤20ppm | Complies |
Residue on ignition | ≤0.1% | Complies |
Related substances | Biggest Impurities≤0.5% | 0.36% |
Total Impurity≤1.0% | 0.7% | |
Assay | 97.0%~103.0% | 99.3% |
Conclusion | Complies with In-house Standard |
Contact Person: Sales Manager
Tel: +8613429837396